Isolation and Characterization of a Novel Recombinant Classical Pseudorabies Virus in the Context of the Variant Strains Pandemic in China
Viruses · 2023
DOI: 10.3390/v15091966 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Zhengmin Lian und 8 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, College of Veterinary Medicine, Yangzho…. Hauptthemen laut MEDLINE: Herpesvirus 1, Suid, Pseudorabies, Swine Diseases. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Postgraduate Research and Practice Innovation Program of Jiangsu Province (Yangzhou University), Project of the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).
Abstract (Originalsprache)
Pseudorabies virus (PRV) variants were discovered in immunized pigs in Northern China and have become the dominant strains since 2011, which caused huge economic losses. In this study, a classical PRV strain was successfully isolated in a PRV gE positive swine farm. The complete genome sequence was obtained using a high-throughput sequencing method and the virus was named JS-2020. The nucleotide homology analysis and phylogenetic tree based on complete genome sequences or gC gene showed that the JS-2020 strain was relatively close to the classical Ea strain in genotype II clade. However, a large number of amino acid variations occurred in the JS-2020 strain compared with the Ea strain, including multiple immunogenic and virulence-related genes. In particular, the gE protein of JS-2020 was similar to earlier Chinese PRV strains without Aspartate insertion. However, the amino acid variations analysis based on major immunogenic and virulence-related genes showed that the JS-2020 strain was not only homologous with earlier PRV strains, but also with strains isolated in recent years. Moreover, the JS-2020 strain was identified as a recombinant between the GXGG-2016 and HLJ-2013 strains. The pathogenicity analysis proved that the PRV JS-2020 strain has typical neurogenic infections and a strong pathogenicity in mice. Together, a novel recombinant classical strain was isolated and characterized in the context of the PRV variant pandemic in China. This study provided some valuable information for the study of the evolution of PRV in China.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China.
- Luoyang Putai Biotech Co., Ltd., Luoyang 471003, China.
ORCID-Profile: Xiangdong Li
Förderung
- National Natural Science Foundation of China
- Postgraduate Research and Practice Innovation Program of Jiangsu Province (Yangzhou University)
- Project of the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)
Zitieren
APA
Lian, Z., Liu, P., Zhu, Z., Sun, Z., Yu, X., Deng, J., Li, R., Li, X., & Tian, K. (2023). Isolation and Characterization of a Novel Recombinant Classical Pseudorabies Virus in the Context of the Variant Strains Pandemic in China. Viruses. https://doi.org/10.3390/v15091966
Vancouver
Lian Z, Liu P, Zhu Z, Sun Z, Yu X, Deng J, et al. Isolation and Characterization of a Novel Recombinant Classical Pseudorabies Virus in the Context of the Variant Strains Pandemic in China. Viruses. 2023. doi:10.3390/v15091966
BibTeX
@article{Lian2023,
author = {Lian, Zhengmin and Liu, Panrao and Zhu, Zhenbang and Sun, Zhe and Yu, Xiuling and Deng, Junhua and Li, Ruichao and Li, Xiangdong and Tian, Kegong},
title = {Isolation and Characterization of a Novel Recombinant Classical Pseudorabies Virus in the Context of the Variant Strains Pandemic in China},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15091966}
}
EUVIMED